Bavarian Nordic (OTCPK:BVNR.Y) - Aandelenkoers, Nieuws & Analyse

BVNR.Y Overzicht aandelen

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Meer informatie

BVNR.Y fundamentele analyse
Sneeuwvlok Score
Waardering	5/6
Toekomstige groei	0/6
Prestaties in het verleden	5/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

Verhandeld tegen 62% onder onze schatting van de reële waarde

De winst groeide het afgelopen jaar met 54.6%

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 3.6% per jaar dalen.

Bavarian Nordic A/S Concurrenten

MannKind

NasdaqGM:MNKD

US$1.9b

Catalyst Pharmaceuticals

NasdaqCM:CPRX

US$2.5b

ADMA Biologics

NasdaqGM:ADMA

US$4.5b

Agios Pharmaceuticals

NasdaqGS:AGIO

US$3.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Bavarian Nordic
Historische aandelenkoersen
Huidige aandelenkoers	DKK 8.72
52 Week Hoogtepunt	DKK 14.60
52 Week Laag	DKK 6.86
Bèta	1.58
11 maand verandering	-17.23%
3 maanden verandering	-31.01%
1 Jaar Verandering	16.34%
33 jaar verandering	-43.01%
5 jaar verandering	6.73%
Verandering sinds IPO	47.63%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	BVNR.Y	US Biotechs	US Markt
7D	-11.0%	-10.3%	-2.1%
1Y	16.3%	13.6%	29.6%

Rendement versus industrie: BVNR.Y presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 13.6 % opleverde.

Rendement versus markt: BVNR.Y presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 29.6 % opleverde.

Prijsvolatiliteit

Is BVNR.Y's price volatile compared to industry and market?
BVNR.Y volatility
BVNR.Y Average Weekly Movement	6.7%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	3.1%

Stabiele aandelenkoers: BVNR.Y heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van BVNR.Y is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1992	1,609	Paul Chaplin	www.bavarian-nordic.com

Bavarian Nordic A/S ontwikkelt, produceert en verkoopt levensreddende vaccins. Het bedrijf biedt niet-replicerende pokken- en apenpokkenvaccins onder de namen IMVAMUNE, IMVANEX en JYNNEOS; rabiësvaccin voor menselijk gebruik onder de naam Rabipur/RabAvert; tekenencefalitisvaccin onder de naam Encepur; en ebolavaccin onder de naam MVABEA. Het ontwikkelt ook MVA-BN voor de behandeling van pokken; MVA-BN RSV, dat zich in Fase III van de klinische testen bevindt voor de behandeling van respiratoir syncytieel virus; ABNCoV2 dat Fase III van de klinische testen voor de behandeling van SARS-CoV-2 heeft afgerond.

Bavarian Nordic A/S Samenvatting

Hoe verhouden de winst en inkomsten van Bavarian Nordic zich tot de beurswaarde?
BVNR.Y fundamentele statistieken
Marktkapitalisatie	US$2.05b
Inkomsten(TTM)	US$157.86m
Inkomsten(TTM)	US$856.60m

13.0x

Koers/Winstverhouding

2.4x

P/S-verhouding

Is BVNR.Y overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
BVNR.Y resultatenrekening (TTM)
Inkomsten	DKK 6.07b
Kosten van inkomsten	DKK 2.33b
Brutowinst	DKK 3.74b
Overige uitgaven	DKK 2.62b
Inkomsten	DKK 1.12b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

Mar 05, 2025

Winst per aandeel (EPS)	14.24
Brutomarge	61.57%
Nettowinstmarge	18.43%
Schuld/Eigen Vermogen Verhouding	0.1%

Hoe presteerde BVNR.Y op de lange termijn?

Bekijk historische prestaties en vergelijking

BVNR.Y Overzicht aandelen

Beloningen

Risicoanalyse

Bavarian Nordic A/S Concurrenten

NasdaqGM:MNKD

US$1.9b

NasdaqCM:CPRX

US$2.5b

NasdaqGM:ADMA

US$4.5b

NasdaqGS:AGIO

US$3.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Recent updates

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication for Bavarian Nordic's Mpox Vaccine

Bavarian Nordic A/S Upgrades Earnings Guidance for the Year 2024

Bavarian Nordic A/S Receives EMA Approval of Mpox Vaccine for Adolescents

Bavarian Nordic Receives WHO Prequalification for Mpox Vaccine

Bavarian Nordic A/S Announces First Doses of its Mpox Vaccine, Mva-BN

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Singapore

Bavarian Nordic A/S, Annual General Meeting, Apr 09, 2025

Bavarian Nordic A/S to Report Fiscal Year 2024 Results on Mar 05, 2025

Bavarian Nordic A/S Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents

Bavarian Nordic A/S Receives Positive Chmp Opinion for Including Mpox Real-World Effectiveness Data in European Marketing Authorization for Smallpox and Mpox Vaccine

Bavarian Nordic A/S Receives EMA Filing Acceptance and Validation of the MAA for Its Chikungunya Vaccine

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic Reports Omicron Data from Phase 2 Trial of Its Covid-19 Booster Vaccine Candidate

Bavarian Nordic Announces Initiation of A Global Phase 3 Clinical Trial of Its RSV Vaccine Candidate in Older Adults

Bavarian Nordic A/S Provides Revenue Guidance for the Full Year of 2022

Bavarian Nordic A/S Reports Additional Positive Phase 2 Results for Its Covid-19 Vaccine Candidate Ahead of Phase 3 Trial

Bavarian Nordic Announces Breakthrough Therapy Designation for Its RSV Vaccine Candidate for the Prevention of Respiratory Syncytial Virus in Older Adults

Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening its Capital Base

Bavarian Nordic A/S announced a financing transaction

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2021

Bavarian Nordic Initiates Phase 2 Clinical Trial of COVID-19 Booster Vaccine

Bavarian Nordic A/S Reports Initial Results from First-in-Human Trial of COVID-19 Vaccine

Bavarian Nordic A/S Maintains Earnings Guidance for the Full Year 2021

Bavarian Nordic A/S has completed a Follow-on Equity Offering in the amount of DKK 1.14845 billion.

Bavarian Nordic A/S Reports Encouraging Preclinical Data for COVID-19 Vaccine Candidate Ahead of First-in-Human Trial